Scientists and clinicians at NTNU and St. Olavs hospital have worked for years on developing and testing the technology providing the foundation for our non-pharmacological solution for preventing migraine.
Today the latest findings were made available in the prestigious international scientific journal “Headache”. The results show that:
1. The intervention is safe and tolerable.
2. Usability scores were consistently high.
3. The biofeedback optimization algorithm had excellent correlation to the raw physiological measurements.
These results are encouraging news for the future care of migraine sufferers. Further development and clinical trials are ongoing.